These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23499437)

  • 1. Hepatitis C treatment: interferon free or interferon freer?
    Dusheiko G; Burney T
    Lancet; 2013 Jun; 381(9883):2063-5. PubMed ID: 23499437
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
    J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Rodriguez-Torres M; Lawitz E; Kowdley KV; Nelson DR; Dejesus E; McHutchison JG; Cornpropst MT; Mader M; Albanis E; Jiang D; Hebner CM; Symonds WT; Berrey MM; Lalezari J
    J Hepatol; 2013 Apr; 58(4):663-8. PubMed ID: 23183528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the treatment of hepatitis C genotypes 2-6.
    Paterson JC; Miller MH; Dillon JF
    Curr Opin Infect Dis; 2014 Dec; 27(6):540-4. PubMed ID: 25313502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Mangia A; Piazzolla V
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S179-85. PubMed ID: 25458780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
    Delabaudière C; Lavayssière L; Dörr G; Muscari F; Danjoux M; Sallusto F; Peron JM; Bureau C; Rostaing L; Izopet J; Kamar N
    Transpl Int; 2015 Feb; 28(2):255-8. PubMed ID: 25159822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.
    Kim DY
    Gut Liver; 2014 Jul; 8(4):335-6. PubMed ID: 25071896
    [No Abstract]   [Full Text] [Related]  

  • 10. [Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].
    Izumi N; Kurosaki M; Suzuki S; Tamaki N
    Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2108-11. PubMed ID: 23221060
    [No Abstract]   [Full Text] [Related]  

  • 11. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir-ribavirin duo for chronic hepatitis C.
    Njei B
    Conn Med; 2014; 78(6):355-6. PubMed ID: 25672064
    [No Abstract]   [Full Text] [Related]  

  • 13. Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.
    Romero-Gómez M; Rojas Á
    Hepatology; 2015 Mar; 61(3):744-7. PubMed ID: 25345724
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-free hepatitis C treatment: one pill to fit all?
    Hellard ME; Doyle JS
    Lancet; 2014 Feb; 383(9916):491-2. PubMed ID: 24209978
    [No Abstract]   [Full Text] [Related]  

  • 15. HCV treatment--no more room for interferonologists?
    Drenth JP
    N Engl J Med; 2013 May; 368(20):1931-2. PubMed ID: 23607592
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir for HCV in patients with HIV: where next?
    Osinusi A; Naggie S
    Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748
    [No Abstract]   [Full Text] [Related]  

  • 18. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA
    Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir.
    Stine JG; Cornella S; Shah NL
    Ann Rheum Dis; 2014 Oct; 73(10):e64. PubMed ID: 25038237
    [No Abstract]   [Full Text] [Related]  

  • 20. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.